Condition 1: Attention deficit hyperactivity disorder. Condition 2: sleep disorders. Attention-deficit hyperactivity disorders Sleep disorders not due to a substance or known physiological condition
Conditions
Interventions
Intervention 1: Intervention group 1: Intervention group 1: For 4 weeks, they will be treated with methylphenidate with rapid release made by Pursina company and then for 1 week without drug and then
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: adult Patients diagnosis attention deficit hyperactivity disorder start treatment with methylphenidate
Exclusion criteria
Exclusion criteria: History of taking any stimulant in the past month Drug abuse Taking sleeping pills such as benzodiazepines or zolpidem Major psychiatric disorders such as bipolar disorder, psychotic disorders, autism and major depression Severe hypertension, heart failure, arrhythmia, hyperthyroidism and thyrotoxicosis, myocardial infarction and angina, glaucoma History of tics and Toure syndrome Existence of neurological diseases that accompany sleep disorders such as epilepsy, vascular disorders, history of stroke, movement and Parkinson's disorders, dementia and cognitive disorders Serious side effects of methylphenidate such as seizures Patient dissatisfaction with entering or continuing the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| . Anxiety, daily activity, duration and quality of sleep at the beginning and end of each period with the Pittsburgh Questionnaire. Timepoint: At the beginning of the study and at 4 and 8 weeks of treatment. Method of measurement: Face-to-face interview with the patient.;Epworth Sleepiness Scale. Timepoint: At the beginning of the study and at 4 and 8 weeks of treatment. Method of measurement: Face-to-face interview with the patient. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMasoud Esfahani
Tehran University of Medical Sciences
Outcome results
None listed